✦ LIBER ✦

Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus

✍ Scribed by J.S. PASRICHA; J. THANZAMA; UTTAM KUMAR KHAN

Book ID: 108661305
Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 301 KB
Volume: 119
Category: Article
ISSN: 0007-0963
DOI: 10.1111/j.1365-2133.1988.tb07104.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pituitary–adrenal function following dex

Pituitary–adrenal function following dexamethasone–cyclophosphamide pulse therapy for pemphigus

✍ L. Kumrah; M. Ramam; P. Shah; R.M. Pandey; J.S. Pasricha 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

CURATIVE EFFECT OF DEXAMETHASONE-CYCLOPH

CURATIVE EFFECT OF DEXAMETHASONE-CYCLOPHOSPHAMIDE PULSE THERAPY FOR THE TREATMENT OF PEMPHIGUS VULGARIS

✍ J.S. PASRICHA; SIDDHARTHA S. DAS 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB

High-dose dexamethasone therapy for resi

High-dose dexamethasone therapy for resistant autoimmune thrombocytopenic purpura

✍ Bertrand Godeau; Phiuppe Bierung; Eric Oksenhendler; Sylvie Castaiqne; Eric Deco 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

Effective therapy for Burkitt's lymphoma

Effective therapy for Burkitt's lymphoma: High-dose cyclophosphamide + high-dose methotrexate with coordinated intrathecal therapy

✍ Irma Ramirez; Margaret P. Sullivan; Yeu-ming Wang; R. G. Martin; J. J. Butler 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 561 KB

Indications for high-dose dexamethasone

Indications for high-dose dexamethasone therapy in respiratory distress syndrome

✍ P. L. P. Brand; E. Verhagen; I. M. J. Rosina-Angelista; S. Bambang Oetomo 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 362 KB

Metronomic therapy with cyclophosphamide

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

✍ L. Michael Glode; Albaha Barqawi; Frances Crighton; E. David Crawford; Robert Ke 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Abstract ## BACKGROUND The current study was designed to evaluate the efficacy and toxicity of the continuous oral administration of a combination of cyclophosphamide (50 mg/day given in the morning) and dexamethasone (1 mg/day given in the evening) in patients with prostate specific antigen (P